Physics| Volume 18, ISSUE 3, P387-395, May 2019

Monte Carlo study of the relationship between skin dose and optically stimulated luminescence dosimeter dose in Pd-103 permanent breast seed implant brachytherapy

  • Steven Nich
    Corresponding author. Department of Physics and Astronomy, University of Calgary, 2500 University Drive NW, Calgary, Alberta T2N 1N4, Canada. Tel.: +1-403-521-3085; fax: +1-403-521-3327.
    Department of Physics and Astronomy, University of Calgary, Calgary Alberta, Canada
    Search for articles by this author
  • Charles Kirkby
    Department of Physics and Astronomy, University of Calgary, Calgary Alberta, Canada

    Department of Oncology, University of Calgary, Calgary Alberta, Canada

    Department of Medical Physics, Jack Ady Cancer Centre, Lethbridge, Alberta, Canada
    Search for articles by this author
  • J. Eduardo Villarreal-Barajas
    Department of Physics and Astronomy, University of Calgary, Calgary Alberta, Canada

    Department of Medical Physics, Royal Devon and Exeter Hospital NHS, Exeter, Devon, UK
    Search for articles by this author
Published:February 18, 2019DOI:



      To establish a method for estimating skin dose for patients with permanent breast seed implant based on in vivo optically stimulated luminescence dosimeters (OSLDs) measurements.

      Methods and Materials

      Monte Carlo simulations were performed in a simple breast phantom using the EGSnrc user code egs_brachy. Realistic models of the IsoAid Advantage Pd-103 brachytherapy source and Landauer nanoDot OSLD were created to model in vivo skin dose measurements where an OSLD would be placed on the skin of a patient with permanent breast seed implant following implantation. Doses to a 0.2 cm3 volume of skin beneath the OSLD and to the sensitive volume within the OSLD were calculated, and the ratio of these values was found for various seed positions inside the breast phantom. The maximum value of this ratio may be used as a conversion factor that would allow skin dose to be estimated from in vivo OSLD measurements.


      Conversion factors of 0.5 and 1.44 are recommended for OSLDs calibrated to dose to Al2O3 and water, respectively, at the point of measurement in the OSLD. These factors were not significantly affected by the addition of extra seeds in the dose calculations.


      A method for estimating skin dose from OSLD measurements was proposed. Individual institutions should calibrate OSLDs to Pd-103 seeds to apply the results of this work clinically.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Njeh C.F.
        • Saunders M.W.
        • Langton C.M.
        Accelerated partial breast irradiation (APBI): a review of available techniques.
        Radiat Oncol. 2010; 5: 90
        • Pignol J.P.
        • Rakovitch E.
        • Keller B.M.
        • et al.
        Tolerance and acceptance results of a palladium-103 permanent breast seed implant phase I/II study.
        Int J Radiat Oncol Biol Phys. 2009; 73: 1482-1488
        • Mashouf S.
        • Fleury E.
        • Lai P.
        • et al.
        Clinical significance of accounting for tissue heterogeneity in permanent breast seed implant brachytherapy planning.
        Int J Radiat Oncol Biol Phys. 2016; 94: 816-823
        • Rivard M.J.
        • Coursey B.M.
        • DeWerd L.A.
        • et al.
        Update of AAPM task group no. 43 report: a revised AAPM protocol for brachytherapy dose calculations.
        Med Phys. 2004; 31: 633-674
        • Zehtabian M.
        • Faghihi R.
        • Si S.
        A review on main defects of TG-43.
        in: Kishi K. Brachytherapy. Chapter 1. InTech, 2012: 3-16
        • Afsharpour H.
        • Pignol J.P.
        • Keller B.
        • et al.
        Influence of breast composition and interseed attenuation in dose calculations for post-implant assessment of permanent breast103Pd seed implant.
        Phys Med Biol. 2010; 55: 4547-4561
        • Beaulieu L.
        • Carlsson Tedgren Å.
        • Carrier J.F.
        • et al.
        Report of the task group 186 on model-based dose calculation methods in brachytherapy beyond the TG-43 formalism: current status and recommendations for clinical implementation.
        Med Phys. 2012; 39: 6208-6236
        • Reft C.S.
        The energy dependence and dose response of a commercial optically stimulated luminescent detector for kilovoltage photon, megavoltage photon, and electron, proton, and carbon beams.
        Med Phys. 2009; 36: 1690-1699
        • Poirier Y.
        • Kuznetsova S.
        • Villarreal-Barajas J.E.
        Characterization of nanoDot optically stimulated luminescence detectors and high-sensitivity MCP-N thermoluminescent detectors in the 40-300 kVp energy range.
        Med Phys. 2018; 45: 402-413
        • Chamberland M.J.
        • Taylor R.E.
        • Rogers D.W.
        • et al.
        Egs-brachy: a versatile and fast Monte Carlo code for brachytherapy.
        Phys Med Biol. 2016; 61: 8214-8231
        • Scarboro S.B.
        • Cody D.
        • Alvarez P.
        • et al.
        Characterization of the nanoDot OSLD dosimeter in CT.
        Med Phys. 2015; 42: 1797-1807
        • Taylor R.E.
        • Rogers D.W.
        The CLRP TG-43 parameter database for brachytherapy | department of physics.
        (Available at)
        • Meigooni A.S.
        • Dini S.A.
        • Awan S.B.
        • et al.
        Theoretical and experimental determination of dosimetric characteristics for ADVANTAGE Pd-103 brachytherapy source.
        Appl Radiat Isot. 2006; 64: 881-887
        • Sowards K.T.
        Monte Carlo dosimetric characterization of the IsoAid ADVANTAGE 103Pd brachytherapy source.
        J Appl Clin Med Phys. 2007; 8: 18-25
        • De Frenne D.
        Nuclear data sheets for A = 103.
        Nucl Data Sheets. 2009; 110: 2081-2256
        • Lehmann J.
        • Dunn L.
        • Lye J.E.
        • et al.
        Angular dependence of the response of the nanoDot OSLD system for measurements at depth in clinical megavoltage beams.
        Med Phys. 2014; 41
        • Mobit P.
        • Agyingi E.
        • Sandison G.
        Comparison of the energy-response factor of LiF and Al2O3in radiotherapy beams.
        Radiat Prot Dosimetry. 2006; 119: 497-499
        • Yaffe M.J.
        • Boone J.M.
        • Packard N.
        • et al.
        The myth of the 50-50 breast.
        Med Phys. 2009; 36: 5437-5443
        • Woodard H.Q.
        • White D.R.
        The composition of body tissues.
        Br J Radiol. 1986; 64: 149-159
        • Hilts M.
        • Halperin H.
        • Morton D.
        • et al.
        Skin dose in breast brachytherapy: defining a robust metric.
        Brachytherapy. 2015; 14: 970-978
        • Hopewell J.W.
        • Trott K.R.
        Volume effects in radiobiology as applied to radiotherapy.
        Radiother Oncol. 2000; 56: 283-288
        • Joiner M.
        Basic Clinical Radiobiology.
        CRC Press, London, UK2009: 375